anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FLOLIPID is contraindicated in the following conditions:

  * Concomitant administration of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products) [see Warnings and Precautions (5.1)].
  * Concomitant administration of gemfibrozil, cyclosporine, or danazol [see Warnings and Precautions (5.1)].
  * Hypersensitivity to any component of this medication [see Adverse Reactions (6.2).]
  * Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels [see Warnings and Precautions (5.3)].
  * Women who are pregnant or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Because HMG-CoA reductase inhibitors (statins) decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, simvastatin may cause fetal harm when administered to a pregnant woman. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of use with simvastatin during pregnancy; however, in rare reports congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, simvastatin revealed no evidence of teratogenicity. FLOLIPID should be administered to women of childbearing age only when such patients are highly unlikely to conceive. If the patient becomes pregnant while taking this drug, FLOLIPID should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1)] . 
  * Nursing mothers. It is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require treatment with FLOLIPID should not breastfeed their infants [see Use in Specific Populations (8.3)].
Disruption of circadian rhythm during pregnancy produces adverse health outcomes in offspring; however, the role of maternal circadian rhythms in the immune system of infants and their susceptibility to inflammation remains poorly understood. Here we show that disruption of circadian rhythms in pregnant mice profoundly aggravates the severity of neonatal inflammatory disorders in both male and female offspring, such as necrotizing enterocolitis and sepsis. The diminished maternal production of docosahexaenoic acid (DHA) and the impaired immunosuppressive function of neonatal myeloid-derived suppressor cells (MDSCs) contribute to this phenomenon. Mechanistically, DHA enhances the immunosuppressive function of MDSCs via PPARγ-mediated mitochondrial oxidative phosphorylation. Transfer of MDSCs or perinatal supplementation of DHA relieves neonatal inflammation induced by maternal rhythm disruption. These observations collectively demonstrate a previously unrecognized role of maternal circadian rhythms in the control of neonatal inflammation via metabolic reprograming of myeloid cells.
FIELD: pharmaceutical industry. SUBSTANCE: invention describes adenosine derivatives of general formula (I): R 1  wherein R 2  is hydrogen atom, halogen atom, lower alkyl, lower-O-alkyl, lower-S-alkyl or phenyl and is in 2-or 5-position of indole; n is 0.1 or 2; C 3 -C 7  is lower alkyl, lower alkenyl, lower alkynyl; -NR 6 R 7  cycloalkyl or lower-O-alkyl, phenyl optionally substituted by one to four substituents selected from halogen atom, nitro, lower alkyl or O-alkyl or R 6  wherein R 7  and R 2  are hydrogen atom, lower alkyl, pyridyl, thienyl, naphthyl; and when n is 2, NR 8 R 9  is R 8  wherein R 9  and R 3  are simultaneously lower alkyl or together with nitrogen atom to which they are attached, form heterocycle selected from morpholine or piperidine; R 4  and R 11 , identical or different, are hydrogen atom or lower alkyl, having analgetic and antihypertensive activities. Method of preparing compounds of formula (I) comprises reacting amine of general formula (II): COR 5  with 7-halogenpyrine riboside of general formula (III): R 5  wherein X is halogen atom; CH 2 OH is R 12  wherein R 13  is as defined above, or  , and   and   are protective groups such as acetyl or benzoyl, or together form dioxolane group in solvent such as alcohol or dimethylformamide in the presence of base such as triethyl amine, pyridine or sodium carbonate, or additionally, in the presence of two equivalents of amine at temperatures from 20 C to 140 C, subsequently removing protective groups in basic medium with ammonium hydroxide solution, or in acid medium, with normal hydrochloric acid solution at temperatures between 0 C and 70 C depending on type of protective group. Present invention also describes pharmaceutical compositions based on compound of formula (I) having analgesic and/or antihypertensive activity. EFFECT: improved properties of the pharmaceutical composition. 14, cl, 156 ex, 2 tbl
Patients attend 8 physical therapy visits twice monthly for 4 months or until transplant. Patients also undergo an individualized exercise program at home for 6 months. The program comprises 3 main components: walking over 30 minutes twice a week, strengthening and balance retraining exercise over 30 minutes three times a week.
PURPOSE:To extract the component of ginseng useful as a medicinal nutrient food, in the garlic juice, in a short time, by immersing a ginseng in garlic juice. CONSTITUTION:A ginseng is immersed in garlic juice to release the medicinal components of the ginseng in the garlic juice. The whole process is carried out as follows. A fresh or dried root of ginseng of 4 or 6 years old is immersed in about 1kg of garlic juice for about 7 days with occasional inspection of the appearance. The dried root is dilated to about 1.5 times the original size, and about 10 days after the immersion, the water and the medicinal components are entirely transferred to the garlic juice leaving the root free from bitter taste and giving the garlic juice having bitter taste and herb smell characteristic of ginseng. In the case of a fresh ginseng, almost all components are released to the garlic juice after 10-15 days of immersion, leaving the fibrous tissue of the root. The medicinal effect of ginseng can doubled by the administration of the garlic juice containing ginseng extract.
BACKGROUND: The endovascular repair of infrarenal abdominal aortic aneurysms can be performed with a wide variety of devices. Many of these grafts elevate the aortic bifurcation which can limit future repairs if the graft material fails thereby creating a type III endoleak to aorto-uniliac grafts. Many manufacturers have grafts susceptible to this, but we have seen this in the Medtronic AneuRx graft. Our goal is to provide technical details and outcomes regarding a novel technique to reline these grafts while maintaining inline flow to the iliac arteries.
METHODS: This was a single-institution review of patients who had endoleaks requiring intervention after a previously placed graft with an elevated aortic bifurcation. Primary outcomes included technical success defined as placement of all planned devices, resolution of type III endoleak, aneurysm size at follow-up, and requirement of reintervention. Secondary outcomes included 30-day complications, aneurysm-related mortality, and all-cause mortality. Technical details of the operation include back-table deployment of an Ovation device, modification of the deployment system tether and pre-emptive placement of an up and over 0.014″ wire. The wire is placed up and over and hung outside the contralateral gate. Once the main body is introduced above the old graft, the 0.014" is snared from the contralateral side and externalized. The main body is then able to be seated at the bifurcation as the limb is not fully deployed and then device deployment is completed per instructions for use.
RESULTS: Our study consists of 4 individuals, 3 of which had an abdominal aortic aneurysm initially managed with an AneuRx endovascular aneurysm repair and 1 with a combination of Gore and Cook grafts. All 4 patients were male with an average age of 84.5 years at time of reline. All patients had at least 10 years between initial surgery and reline at our institution. Primary outcomes revealed no type 1 or 3 endoleaks at follow-up, technical success was 100% and 1 patient required reintervention for aneurysm growth and type 2 endoleak. In terms of our secondary outcomes, there was 1 postoperative complication which was cardiac dysfunction secondary to demand ischemia, aneurysm-related mortality was 0% and all-cause mortality was 25% at average follow-up of 2.44 years.
CONCLUSIONS: As individuals continue to age, there are more patients who would benefit from less invasive reinterventions following endovascular aneurysm repair. Whether this is due to aortic degeneration, stent migration, or stent material damage is not always known. In this study, we present an endovascular approach to treating type III endoleak patients with a previous graft and elevated aortic bifurcation using Ovation stent grafts and found no evidence of type 1 or 3 endoleaks on follow-up imaging. This approach may allow patients with type III endoleak the option of a minimally invasive, percutaneous approach where they previously would not have had one.
This is a non-primate vitreal replacement process that quantitates the inflammatory response to viscoelastic agents or solutions. More specifically, the rabbit vitreal replacement process consists of the surgical replacement of a small volume of the central gel vitreous of the rabbit with a viscoelastic agent or solution, and measuring the invasion of white blood cells in the vitreous and anterior chamber at 48 hours post injection. Additional parameters measured are anterior chamber flare, haze and flare in the vitreal chamber, ocular fundus clarity, presence of iris congestion, lens involvement, corneal clarity, conjunctival congestion and conjunctival swelling. In this process, the rabbit is evaluated prior to injection of the viscoelastic agent or solution and 48 hours post injection. Each parameter is evaluated on a scale of 0 to 5. A non-inflammatory sample consists of a mean total score of equal to or less than one or a vitreal cell count less than 50 cells/mm 3 . This is an extremely sensitive system for detecting small amounts of inflammatory agents in viscoelastic agents or solutions. The test solution is rated as acceptable for veterinary or human use if a non-inflammatory response is obtained in this process.
There are over 312,000 Veterans living in the state of Oklahoma \[2\]. The Coffee Bunker is a non-profit community agency in Tulsa, Oklahoma that serves as the flagships program for Serving Our Service Members (S.O.S). The Coffee Bunker's mission is to offer support to service members and Veterans by helping them reintegrate back into their families and communities. The overall purpose of the present study is to work with the Coffee Bunker in offering support towards their mission, specifically in delivering organized parenting programs to service members and Veterans.

Challenges of reintegration after a military deployment can increase levels of stress for Veterans, spouses, and their children. In fact, it is common for Veterans or service members who struggle with reintegration in their family to report feelings of isolation and lack of perceived control, which may impact their ability to parent effectively. The struggles of parents can negatively impact the functioning of the family, such that children may exhibit more behavioral problems and Veterans parents may be more vulnerable to mental health symptomology \[3, 4\]. Fortunately, research suggests that positive and effective parenting practices can mitigate family stressors \[5, 6\]. As such, given the stressors of reintegration among military families, it may be advantageous to implement an evidence-based psychoeducation parenting program tailored to Veterans. The goals of the parenting program are to assist in improving parent's sense of competence, improving parent's emotional regulation abilities, and lower parental stress. The current project will be evaluating possible benefits from an evidence-based parenting program with military families. The parenting program is free, and is offered by the investigators as a community service. Participation in the parenting program does not obligate enrollment in the study. This is made possible by one of the PI's (Zanotti's) Schweitzer Fellowship; Zanotti is conducting the parenting program along with Dr. Cromer, as a community service.

The research portion of this study will be voluntary, and while participants will be recruited from the parenting program, it will be made clear that they can opt into the parenting program without doing any of the research measures. The research portion evaluates whether participation in the parenting program reduces parenting stress, increases feelings of parenting competence, and improves parenting practices. This study is unique in that evidence-based practices will be delivered in a manner that incorporates aspects of military culture (i.e., language and concepts are tailored to that used within military culture). The parenting program will incorporate mindfulness and values-based parenting principles. Mindfulness and acceptance and commitment therapy have been shown to be effective in treating service members \[1\] and this will be the first study that examines how learning these principles do or do not impact parenting stress, competence, and practices.
The 2nd Medical Department admits patients with acute arterial occlusion at the stage of critical limb ischaemia. The poorest prognosis considering preservation of the limb is shown by the patients who exhibit symptoms of ischaemia due to affected popliteal artery and arteries of the shank in the the popliteal artery aneurysm. On the other hand, diagnosis of this condition is prompt and easy (general ultrasound scan below the knee). Patients with the popliteal artery aneurysm, confirmed by ultrasound investigation, and concurrent signs and symptoms of acute critical ischaemia will be indicated for catheterization intervention at our unit, which will confirm morphological compatibility with endovascular occlusion of the aneurysm sac through implantation of a peripheral stent graft, supported by implantation of a peripheral flexible stent, and at the same time insertion of a thrombolytic catheter into the implanted stent graft for local thrombolysis of tibial arteries if required by the current situation. The patient will be hospitalized at the angiology intensive care unit of the 2nd Medical Department, where local intra-arterial thrombolytic therapy will be performed according to the standard protocol. After completion of the proper endovascular treatment, the patients will be transferred to combined peroral anticoagulation and antiaggregation treatment, and all of them will have an ultrasound scan below the knee, with the readings archived for the purpose of further comparison and monitoring. Subsequently, the patients will be monitored in the outpatient regime after 6 weeks, 3, 6 and 12 months. At each visit, clinical examination will be done including establishment of ABI/TBI values and ultrasound investigation of the region below the knee.
OBJECTIVES: Stillbirth is an important health problem, and in Mexico, only half of the stillbirths have an explainable cause. The aim of this study was to implement a multidisciplinary workup to identify the etiology and potential risk factors for stillbirth at the Hospital Universitario "Dr. José Eleuterio González".
METHODS: This is a prospective, descriptive, observational study that included stillbirths from the Obstetrics Service from October 1st, 2019 to May 25, 2020. Evaluation strategies included a complete maternal medical history, physical examination of the fetus, and a photographic medical record. For every stillbirth either a prenatal ultrasound, a postnatal x-ray, or a fetal autopsy, were needed. Multiplex Ligation Probe Amplification (MLPA) was performed with an umbilical cord sample.
RESULTS: Thirty-three stillbirths were reported; 21 were included in the analysis. Eleven women (52.3%) had known risk factors for stillbirth, mainly elevated body mass index and diabetes. On physical examination, external birth defects were found in 8 fetuses (38%). X-ray was performed in 14 cases (66%), alterations were detected as a probable etiologic cause just in one. All cases underwent MLPA, which were reported negative. Three cases had criteria for autopsy. Findings were inconclusive to determine etiology.
CONCLUSIONS: The best tools for evaluation of stillbirth were the elaboration of clinical history, physical examination, and prenatal ultrasound. Diabetes and obesity were the most frequent risk factors found in our population. These factors are preventable by implementing strategies that lead to better prenatal care.
Mechanisms for optimizing the determination of supplements for consumers are provided. A longevity inquiry is received from a remote device. A biological extraction is retrieved from a user database and is used with the longevity inquiry to identify a longevity element associated with a user. Further, an ADME model is selected that uses the biological extraction. A machine-learning algorithm is generated using the selected ADME model that uses the longevity element associated with the user as an input and outputs an ADME factor. A tolerant longevity element is identified utilizing the ADME factor.
Open-label. There will be 4 cohorts receiving once-weekly doses (part 2 cohorts 1, 2, 3 and 5) and one cohort receiving once-monthly doses (part 2 cohort 4). Participants will continue into the part 2 extension on the same treatment regimen.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 

The safety data described in this section reflect exposure to a one-time intravenous infusion of ELEVIDYS in 156 male patients with a confirmed mutation of the DMD gene in four clinical studies, including one completed open-label study, one ongoing open-label study, and two studies that included a double-blind, placebo-controlled period. Prior to ELEVIDYS infusion, patients in the ELEVIDYS treatment group had a mean age of 6.7 years (range: 3 to 20) and mean weight of 24.6 kg (range: 12.5 to 80.1). 144 patients received the recommended dose of 1.33 × 1014 vg/kg, and 12 received a lower dose. Table 3 below presents adverse reactions from these four clinical studies. 

The most common adverse reactions (incidence ≥5%) across all studies are summarized in Table 3. 

Adverse reactions were typically seen within the first 2 weeks (nausea, vomiting, thrombocytopenia, pyrexia), or within the first 2 months (immune-mediated myositis, liver injury). Vomiting may occur as early as on the day of the infusion. 

In the double-blind, placebo-controlled trial, Study 3 Part 1, patients 4 to 7 years of age (N=125) received either ELEVIDYS (N=63) at the recommended dose of 1.33 × 1014 vg/kg or placebo (N=62). Table 4 below presents the most frequent adverse reactions from Study 3 Part 1.
Breast augmentation is the most commonly performed aesthetic surgery procedure in women worldwide. The use of the subfascial plane has been suggested to decrease the incidence of capsular contracture compared with the subglandular plane, while simultaneously avoiding the complication of animation deformity in the subpectoral plane. The aim of this systematic review and meta-analysis was to compare the adverse outcomes of subfascial vs subglandular planes in breast augmentation. This review was registered a priori on OSF (https://osf.io/pm92e/). A search from inception to June 2023 was performed on MEDLINE, Embase, and CENTRAL. A hand search was also performed. All randomized and comparative cohort studies that assessed the use of the subfascial plane for breast augmentation were included. Outcomes evaluated included the incidences of seroma, hematoma, infection, rippling, capsular contracture, and revision surgery. Ten studies were included in this systematic review. Three randomized controlled trials and 7 comparative cohort studies were used for quantitative synthesis. There was a significant difference favoring subfascial compared with subglandular planes in the incidence of hematoma, rippling, and capsular contracture. All included studies had a high risk of bias. The current evidence suggests that the subfascial plane for breast augmentation decreases the risk of capsular contracture, hematoma, and rippling compared with the subglandular plane. Further randomized evidence with high methodological rigor is still required to validate these findings.
Microcrystalline cellulose 4.5mg OD PO. Capsules are masked and provided in blister packs.
The study objective is to compare the efficacy and safety of albuterol in a dry powder inhaler (DPI) and albuterol in an HFA metered dose inhaler (MDI) after a cumulative dose of 1440mcg administered as 1+1+2+4+8 inhalations (90mcg per inhalation). Another study objective is to compare the pharmacokinetics (metabolism) of albuterol with the two inhalers. The pharmacokinetics of albuterol will be examined in half (24) of the study subjects. To participate in the study, patients must provide written informed consent, washout any prohibited medications and pass all the screen criteria. Once this is done, there will be two treatment visits. At each visit the subject will inhale with both types of inhalers. At each visit, one inhaler will have active drug (albuterol) and one inhaler will have placebo (dummy). The inhaler with the active drug will be switched at the two visits in a random manner. At each visit the subject will inhale with each inhaler a total of 16 times by a specific schedule. The subject will inhale from each inhaler once (1), wait 30 minutes, inhale from each inhaler once (1), wait 30 minutes, inhale from each inhaler twice (2), wait 30 minutes, inhale from each inhaler four times (4), wait 30 minutes, and then inhale from each inhaler eight times (8). The total time to complete the inhalations should be about 2 hours. Following that, there will be a series of assessments taken at regular times with vital signs measured up to 6 hours, ECG (electrocardiogram) assessed up to 4 hours, blood taken to measure potassium and glucose up to 4 hours, lung function evaluated with spirometry up to 6 hours, and for those subjects participating in the pharmacokinetic evaluation blood will be drawn up to 12 hours. The two study treatment visits will be 3 to 14 days apart. Following these visits, there will be a study concluding visit 1 to 5 days later.